Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From 2006 Levels.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c72211) has announced the addition of "Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management strategies" succeed to their offering. Introduction The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orions Stalevo, GlaxoSmithKlines (GSKs) Requip Requip® Ropinirole Pharmacology A 2nd-generation dopamine agonist for treating Parkinson's disease. See Parkinson's disease. Modutab, and UCB-Schwarzs Neupro. Scope Analysis of patient potential, unmet un·met adj. Not satisfied or fulfilled: unmet demands. needs and clinical trial design in PD Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies. Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs. Identification of future market events that are expected to affect PD drug revenues. Highlights GSKs Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation activation /ac·ti·va·tion/ (ak?ti-va´shun) 1. the act or process of rendering active. 2. the transformation of a proenzyme into an active enzyme by the action of a kinase or another enzyme. 3. of dopamine receptors Dopamine receptors are a class of metabotropic G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. with Requip Modutab could have a significant clinical benefit over pulsed agonism Ag´o`nism n. 1. Contention for a prize; a contest. with standard drugs. New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisais E2007, it is lacking in Merck-Serono/Newrons safinamide. Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 2007-2016. Reasons to Purchase Benchmark key late-stage PD compounds against current market leading brands. Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the PD market based on key opinion leader comments. For more information, visit http://www.researchandmarkets.com/reports/c72211 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion